Skip to main content
. Author manuscript; available in PMC: 2017 Dec 15.
Published in final edited form as: Int J Cardiol. 2016 Oct 8;225:371–380. doi: 10.1016/j.ijcard.2016.10.021

Figure 4.

Figure 4

AAV9-JPH2 gene therapy maintains cardiac function after pressure-overload induced pathological remodeling. (A) Representative M-mode echocardiograms of AAV9-Con or AAV9-JPH2 treated mice at 5, 7, and 9 weeks post-TAC. Quantification of (B) ejection fraction (EF), (C) end-diastolic diameter (EDD), and (D) systolic left ventricular posterior wall thickness (LVPW;s) at baseline (0) and 2, 5, 7, and 9 weeks post-TAC. Arrow indicates time of AAV9-JPH2 injection at 3 weeks post-TAC. N=number mice. *P<0.05, **P<0.01, ***P<0.001 between treatment groups at a single time-point; † P<0.0001 for all groups compared to baseline; # P<0.05 and ## P<0.01, ### P<0.001 within groups compared to 2 weeks post-TAC.